Industry News
Pharmaceutical Industry News
Bristol Myers Squibb engaged in Acceleron buyout talks but couldn’t justify the price: report
Bristol Myers Squibb engaged in Acceleron buyout talks but couldn't justify the price: report esagonowsky Wed, 10/13/2021 - 09:10
Olympian joins Eli Lilly to level the field for health inequity in breast cancer
Olympian joins Eli Lilly to level the field for health inequity in breast cancer sharon.coey Wed, 10/13/2021 - 08:00
Eli Lilly’s Verzenio snags first-in-class FDA approval for early breast cancer. But limited label poses a challenge
Eli Lilly's Verzenio snags first-in-class FDA approval for early breast cancer. But limited label poses a challenge aliu Wed, 10/13/2021 - 05:56
Pharma saw huge reputation gains in the last year. It should make sure not to squander them, expert says
Pharma saw huge reputation gains in the last year. It should make sure not to squander them, expert says esagonowsky Tue, 10/12/2021 - 14:56
Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180
Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180 esagonowsky Tue, 10/12/2021 - 11:23
Spinoff or $54B sale? GlaxoSmithKline’s consumer health outfit draws buyout interest: report
Spinoff or $54B sale? GlaxoSmithKline's consumer health outfit draws buyout interest: report aliu Tue, 10/12/2021 - 10:47
Viatris to close former Novartis site in California in January, lay off 75
Viatris to close former Novartis site in California in January, lay off 75 esagonowsky Tue, 10/12/2021 - 09:21
Merck’s oral COVID-19 drug sees India’s Everest Organics hit start on production
Merck's oral COVID-19 drug sees India's Everest Organics hit start on production jkeenan Tue, 10/12/2021 - 08:34
Eyes itching from allergies? Ocular’s Dextenza wins FDA approval as first monthly implant
Eyes itching from allergies? Ocular's Dextenza wins FDA approval as first monthly implant aliu Tue, 10/12/2021 - 05:51
Merck Asks F.D.A. for Emergency Approval of Covid Pill
The company is seeking federal sign-off for the pill to be given to high-risk people sick with Covid. Tens of millions of Americans could be eligible.
Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff
Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff esagonowsky Mon, 10/11/2021 - 15:06
Pacira boosts nonopioid pain portfolio via $450M Flexion buy, with more CVR payments to come
Pacira boosts nonopioid pain portfolio via $450M Flexion buy, with more CVR payments to come aliu Mon, 10/11/2021 - 11:27
Pacira boosts non-opioid pain portfolio via $450M Flexion buy, with more CVR payments to come
Pacira boosts non-opioid pain portfolio via $450M Flexion buy, with more CVR payments to come aliu Mon, 10/11/2021 - 11:27
Ipsen poaches Novartis vet Mari Scheiffele to serve as president of its international specialty care team
Ipsen poaches Novartis vet Mari Scheiffele to serve as president of its international specialty care team esagonowsky Mon, 10/11/2021 - 11:06
Ipsen poaches Novartis vet Scheiffele to serve as president of its international specialty care team
Ipsen poaches Novartis vet Scheiffele to serve as president of its international specialty care team esagonowsky Mon, 10/11/2021 - 11:06
Boehringer capacity exceeds original forecast at new $809M Austrian plant
Boehringer capacity exceeds original forecast at new $809M Austrian plant jkeenan Mon, 10/11/2021 - 09:50
Timber posts data on topical Accutane, readies for pivotal trial
Timber posts data on topical Accutane, readies for pivotal trial ntaylor Mon, 10/11/2021 - 09:42
AbbVie’s Botox patent lawsuit is ‘very unlikely to derail’ Revance’s rival launch: analysts
AbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's rival launch: analysts esagonowsky Mon, 10/11/2021 - 09:32
Pfizer calls in the lawyers to block would-be rival to extended-release Xeljanz
Pfizer calls in the lawyers to block would-be rival to extended-release Xeljanz ntaylor Mon, 10/11/2021 - 09:29
GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new home
GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new home aliu Mon, 10/11/2021 - 08:56